Table 1.

Assumptions for models development.

#	Assumption
1	There is active secretion of compounds from blood to the lumen of the kidney's proximal tubules and reverse reabsorption (Liu et al., 2012)
2	Only an unbound drug could be filtrated or secreted from plasma to the lumen of the kidneys
3	The urinary excretion (Qurine) is similar for all compounds
4	Delay (lag) in absorption (Nerella et al., 1993; van der Walt et al., 2013) is included in all models to create a more precise description of plasma PK data
5	The site of action for SGLT2 inhibitors is in the lumen of the kidney's proximal tubules
6	The maximal inhibition level of SGLT2 (Imax) induced by compounds is equal to 1 (100%) (Grempler et al., 2012)
7	All rate equations are to be described as mass action law